BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 31349003)

  • 1. Effect of doxycyline in chronic obstructive pulmonary disease - An exploratory study.
    Singh B; Ghosh N; Saha D; Sarkar S; Bhattacharyya P; Chaudhury K
    Pulm Pharmacol Ther; 2019 Oct; 58():101831. PubMed ID: 31349003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
    Farne HA; Cates CJ
    Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary study: comparative effects of lung volume therapy between slow and fast deep-breathing techniques on pulmonary function, respiratory muscle strength, oxidative stress, cytokines, 6-minute walking distance, and quality of life in persons with COPD.
    Leelarungrayub J; Puntumetakul R; Sriboonreung T; Pothasak Y; Klaphajone J
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3909-3921. PubMed ID: 30584292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy.
    Stynes G; Svedsater H; Wex J; Lettis S; Leather D; Castelnuovo E; Detry M; Berry S
    Respir Res; 2015 Feb; 16(1):25. PubMed ID: 25849223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
    Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.
    Rodrigo GJ; Price D; Anzueto A; Singh D; Altman P; Bader G; Patalano F; Fogel R; Kostikas K
    Int J Chron Obstruct Pulmon Dis; 2017; 12():907-922. PubMed ID: 28360514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-acting Muscarinic Antagonist Versus Inhaled Corticosteroid when Added to Long-acting β-agonist for COPD: A Meta-analysis.
    Oba Y; Chandran AV; Devasahayam JV
    COPD; 2016 Dec; 13(6):677-685. PubMed ID: 27148815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Adding Inhaled Corticosteroid to Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist Therapy Among Patients With Chronic Obstructive Pulmonary Disease.
    Yuasa M; Tanaka Y; Tanaka T; Kashiwada T; Taniuchi N; Saito Y; Seike M; Hino M; Gemma A
    Cureus; 2021 Oct; 13(10):e19168. PubMed ID: 34873511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of inhaled corticosteroids /long-acting agonists in a single inhaler versus inhaled corticosteroids alone on all-cause mortality, pneumonia, and fracture in chronic obstructive pulmonary disease: A nationwide cohort study 2002-2013.
    Cho KH; Kim YS; Linton JA; Nam CM; Choi Y; Park EC
    Respir Med; 2017 Sep; 130():75-84. PubMed ID: 29206637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Effectiveness of Long-Acting Beta
    Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
    Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of long-term doxycycline on lung function & exacerbations: A real-world open, prospective pilot observation on chronic obstructive pulmonary disease.
    Bhattacharyya P; Singh B; Sarkar S; Das SK; Chakraborty B; Saha D; Chakraborty K; Saha I; Chaudhury K
    Indian J Med Res; 2021 Apr; 153(4):465-474. PubMed ID: 34380793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study.
    Casas A; Montes de Oca M; Menezes AM; Wehrmeister FC; Lopez Varela MV; Mendoza L; Ramírez L; Miravitlles M
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1545-1556. PubMed ID: 29785104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations.
    Donohue JF; Worsley S; Zhu CQ; Hardaker L; Church A
    Respir Med; 2015 Jul; 109(7):870-81. PubMed ID: 26006754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of umeclidinium added to inhaled corticosteroid/long-acting β2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study.
    Sousa AR; Riley JH; Church A; Zhu CQ; Punekar YS; Fahy WA
    NPJ Prim Care Respir Med; 2016 Jun; 26():16031. PubMed ID: 27334739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovering the Relative Efficacy of Inhaled Medications for Chronic Obstructive Pulmonary Disease: Multiple Treatment Comparisons.
    Zhu Y; Zhang T; Li H; Yang Y; Chen Q; Kong L; Tai B
    Cell Physiol Biochem; 2017; 41(4):1532-1546. PubMed ID: 28334727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beclometasone for chronic obstructive pulmonary disease.
    De Coster DA; Jones M; Thakrar N
    Cochrane Database Syst Rev; 2013 Oct; (10):CD009769. PubMed ID: 24105424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhaled treatment of COPD: a Delphi consensus statement.
    Ninane V; Corhay JL; Germonpré P; Janssens W; Joos GF; Liistro G; Vincken W; Gurdain S; Vanvlasselaer E; Lehouck A
    Int J Chron Obstruct Pulmon Dis; 2017; 12():793-801. PubMed ID: 28293106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
    Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacological management of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS).
    Albertson TE; Chenoweth JA; Pearson SJ; Murin S
    Expert Opin Pharmacother; 2020 Feb; 21(2):213-231. PubMed ID: 31955671
    [No Abstract]   [Full Text] [Related]  

  • 20. Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD).
    Ni H; Htet A; Moe S
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD011897. PubMed ID: 28631387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.